View in EDS HTML Full Text PDF Full Text

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.

Saved in:
Bibliographic Details
Title: Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.
Authors: Lockshin B; US Dermatology Partners, 15245 Shady Grove Road, Suite 480, Rockville, MD, 20850, USA. blockshin@dermassociates.com., Harrison RW; CorEvitas, LLC, Waltham, MA, USA., McLean RR; CorEvitas, LLC, Waltham, MA, USA., Crabtree MM; CorEvitas, LLC, Waltham, MA, USA., Konicek BW; Eli Lilly and Company, Indianapolis, IN, USA., Zhu B; Eli Lilly and Company, Indianapolis, IN, USA., Malatestinic WN; Eli Lilly and Company, Indianapolis, IN, USA., Atiya B; Eli Lilly and Company, Indianapolis, IN, USA., Murage MJ; Eli Lilly and Company, Indianapolis, IN, USA., Burge RT; Eli Lilly and Company, Indianapolis, IN, USA.
Source: Dermatology and therapy [Dermatol Ther (Heidelb)] 2022 Dec; Vol. 12 (12), pp. 2797-2815. Date of Electronic Publication: 2022 Nov 04.
Publication Type: Journal Article
Journal Info: Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36331713
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lockshin+B%22">Lockshin B</searchLink>; US Dermatology Partners, 15245 Shady Grove Road, Suite 480, Rockville, MD, 20850, USA. blockshin@dermassociates.com.<br /><searchLink fieldCode="AU" term="%22Harrison+RW%22">Harrison RW</searchLink>; CorEvitas, LLC, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22McLean+RR%22">McLean RR</searchLink>; CorEvitas, LLC, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Crabtree+MM%22">Crabtree MM</searchLink>; CorEvitas, LLC, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Konicek+BW%22">Konicek BW</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Zhu+B%22">Zhu B</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Malatestinic+WN%22">Malatestinic WN</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Atiya+B%22">Atiya B</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Murage+MJ%22">Murage MJ</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Burge+RT%22">Burge RT</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101590450%22">Dermatology and therapy</searchLink> [Dermatol Ther (Heidelb)] 2022 Dec; Vol. 12 (12), pp. 2797-2815. <i>Date of Electronic Publication: </i>2022 Nov 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Healthcare+Communications%22">Springer Healthcare Communications </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101590450 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2193-8210 (Print) <i>NLM ISO Abbreviation: </i>Dermatol Ther (Heidelb) <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36331713
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s13555-022-00834-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2797
    Titles:
      – TitleFull: Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lockshin B
      – PersonEntity:
          Name:
            NameFull: Harrison RW
      – PersonEntity:
          Name:
            NameFull: McLean RR
      – PersonEntity:
          Name:
            NameFull: Crabtree MM
      – PersonEntity:
          Name:
            NameFull: Konicek BW
      – PersonEntity:
          Name:
            NameFull: Zhu B
      – PersonEntity:
          Name:
            NameFull: Malatestinic WN
      – PersonEntity:
          Name:
            NameFull: Atiya B
      – PersonEntity:
          Name:
            NameFull: Murage MJ
      – PersonEntity:
          Name:
            NameFull: Burge RT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2022 Dec
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 2193-8210
          Numbering:
            – Type: volume
              Value: 12
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Dermatology and therapy
              Type: main
ResultId 1